Skip to main content
SpringerLink
Log in

Optimal Use of Topical Agents for Allergic Conjunctivitis

  • Disease Management
  • Published:
BioDrugs Aims and scope Submit manuscript

Summary

In recent years, there has been renewed interest in the topical treatment of allergic conjunctivitis, a disorder that is involved in the common red-eye syndrome. Topical treatment for rapid relief of symptoms is most often preferred by the patient, although physicians are more cautious with the choice of an agent that might worsen symptoms due to contact irritation induced by the substance or its preservative. Theoretical advantages of topical over oral administration include a more rapid onset of action, since the active agent is applied directly to the affected tissue, and a reduced potential for systemic adverse effects.

The range of topical agents currently available for the treatment of allergic conjunctivitis varies widely. The 4 primary aims when considering local drug application are: (i) rapid symptomatic relief (particularly applicable to local vasoconstrictors and histamine antagonists); (ii) prophylactic therapy (mast cell stabilisers); (iii) avoidance of systemic adverse reactions (eye drops containing corticosteroids); and (iv) direct route of administration (specific ocular immunotherapy).

In this article we review the underlying pathological mechanisms, present a clinical and diagnostic overview and discuss the available therapeutic options. Finally, we present our treatment strategy, which is based on the nature of the disorder and the patient’s expectations. In seasonal or perennial conjunctivitis the combination of decongestants and antihistamines should be first choice for palliative treatment. Mast cell stabilisers should be used as prophylaxis, while immunotherapy can provide a cure. In vernal and atopic keratoconjunctivitis, the decongestant/antihistamine combination can be used for long-term treatment, while courses of topical corticosteroids may prevent flares. Mast cell stabilisers, with lodoxamide in the first place, are used for prophylactic therapy. Surgery may be useful in handling complications. In giant papillary conjunctivitis, hygienic measures regarding contact lenses are mandatory, and sodium cromoglycate (cromolyn sodium) may provide rapid relief. In contact conjunctivitis, removal or avoidance of the sensitiser is most important. Topical use of corticosteroids should be limited to severe cases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Bonini S, Bonini S. IgE and non-IgE mechanisms in ocular allergy. Ann Allergy 1993 Sep; 71(3): 296–9

    PubMed  CAS  Google Scholar 

  2. Foster CS. The pathophysiology of ocular allergy: current thinking [see discussion pp. 34–8]. Allergy 1995; 50 Suppl. 21: 6–9

    Article  PubMed  CAS  Google Scholar 

  3. Lightman S. Therapeutic considerations: symptoms, cells and mediators [see discussion pp. 34–8]. Allergy 1995; 50 Suppl. 21: 10–13

    Article  PubMed  CAS  Google Scholar 

  4. Montan PG, Biberfeld PJ, Scheynius A. IgE, IgE receptors, and other immunocytochemical markers in atopic and nonatopic patients with vernal keratoconjunctivitis. Ophthalmology 1995 May; 102(5): 725–32

    PubMed  CAS  Google Scholar 

  5. Helleboid L, Khatami M, Wie ZG, et al. Histamine and prostacyclin: primary and secondary release in allergic conjunctivitis. Invest Ophthalmol Vis Sci 1991 Jul; 32(8): 2281–9

    PubMed  CAS  Google Scholar 

  6. Mita H, Sakuma Y, Shida T, et al. Release of chemical mediators in the conjunctival lavage fluids after eye provocation with allergen or compound 48/80 [in Japanese]. Arerugi 1994 Jul; 43(7): 800–8

    PubMed  CAS  Google Scholar 

  7. Fukagawa K, Saito H, Azuma N, et al. Histamine and tryptase levels in allergic conjunctivitis and vernal keratoconjunctivitis. Cornea 1994 Jul; 13(4): 345–8

    Article  PubMed  CAS  Google Scholar 

  8. Abelson MB, Baird RS, Allansmith MR. Tear histamine levels in vernal conjunctivitis and other ocular inflammations. Ophthalmology 1980; 87: 812–4

    PubMed  CAS  Google Scholar 

  9. Elgebaly SA, Donshik PC, Rahhal F, et al. Neutrophil chemotactic factors in the tears of giant papillary conjunctivitis patients. Invest Ophthalmol Vis Sci 1991 Jan; 32(1): 208–13

    PubMed  CAS  Google Scholar 

  10. Lambiase A, Bonini S, Bonini S, et al. Increased plasma levels of nerve growth factor in vernal keratoconjunctivitis and relationship to conjunctival mast cells. Invest Ophthalmol Vis Sci 1995 Sep; 36(10): 2127–32

    PubMed  CAS  Google Scholar 

  11. Rivasi F, Cavallini GM, Longanesi L. Cytology of allergic conjunctivitis: presence of airborne, nonhuman elements. Acta Cytol 1992 Jul–Aug; 36(4): 492–8

    PubMed  CAS  Google Scholar 

  12. Bryant DH, Burns MW, Lazarus L. Identification of IgG antibody as a carrier of reaginic activity in asthmatic patients. J Allergy Clin Immunol 1975; 56: 417–28

    Article  PubMed  CAS  Google Scholar 

  13. Bonini S, Bonini S, Bucci MG, et al. Early and late conjunctival reactions. In: Miyamoto T, Okuda M, editors. Progress in allergy and clinical immunology. Vol. 2. Seattle: Hogrefe & Huber, 1992: 77–82

    Google Scholar 

  14. Lemanske Jr RF, Kalmer MA. Late phase allergic reactions. In: Middleton E, Reed CE, Ellis EF, et al., editors. Allergy: principles and practice. 3rd ed. St Louis: Mosby, 1988: 224–6

    Google Scholar 

  15. Bonini S, Bonini S, Todini V, et al. Late phase ocular reaction induced by conjunctival allergen challenge: a dose response study in humans. J Allergy Clin Immunol 1988; 81: 173

    Article  Google Scholar 

  16. Trocme SD, Bonini S, Barney NP, et al. Late phase reaction in topically induced ocular anaphylaxis in the rat. Curr Eye Res 1988; 7: 437–43

    Article  PubMed  CAS  Google Scholar 

  17. Leonardi A, Secchi AG, Briggs R, et al. Conjunctival mast cells and the allergic late phase reaction. Ophthalmic Res 1992; 24(4): 234–42

    Article  PubMed  CAS  Google Scholar 

  18. Solley GO, Gleich GJ, Jordon RE. The late phase of the immediate wheal and flare skin reaction: its dependence upon IgE antibodies. J Clin Invest 1976; 58: 408–20

    Article  PubMed  CAS  Google Scholar 

  19. Springer T. Adhesion receptors of the immune system. Nature 1990; 346: 425–33

    Article  PubMed  CAS  Google Scholar 

  20. Wegner CD, Gundel RH, Reilly P, et al. Intercellular adhesion molecules-1 (ICAM-1) in the pathogenesis of asthma. Science 1990; 257: 456–9

    Article  Google Scholar 

  21. Canonica GW, Ciprandi G, Pesce GP, et al. ICAM-1 on epithelial cells in allergic subjects: a hallmark of allergic inflammation. Int Arch Allergy Immunol 1995 May–Jun; 107(1–3): 99–102

    Article  PubMed  CAS  Google Scholar 

  22. Canonica GW, Ciprandi G, Buscaglia S, et al. Adhesion molecules of allergic inflammation: recent insights into their functional roles. Allergy 1994 Feb; 49(2): 135–41

    Article  PubMed  CAS  Google Scholar 

  23. Ciprandi G, Pronzato C, Ricca V, et al. Allergen-specific challenge induces intercellular adhesion molecule 1 (ICAM-1 or CD54) on nasal epithelial cells in allergic subjects: relationships with early and late inflammatory phenomena. Am J Respir Crit Care Med 1994 Dec; 150 (6 Pt 1): 1653–9

    PubMed  CAS  Google Scholar 

  24. Ciprandi G, Buscaglia S, Pesce GP, et al. ICAM-1/CD54 expression on conjunctival epithelium during pollen season. Allergy 1995 Feb; 50(2): 184–7

    Article  PubMed  CAS  Google Scholar 

  25. Baudouin CH, Fredj-Reygrobellet D, Gastaud D, et al. HLADR and DQ distribution in normal human ocular structures. Curr Eye Res 1988; 7: 903–11

    Article  PubMed  CAS  Google Scholar 

  26. Baudouin Ch, Haouat N, Brignole F, et al. Immunopathological findings in conjunctival cells using immunofluorescence staining of impression cytology specimens. Br J Ophthalmol 1992; 76: 545–9

    Article  PubMed  CAS  Google Scholar 

  27. Ring J. Epidemiologie allergischer Erkrankungen. Munich: MMV, 1991

    Google Scholar 

  28. Weeke ER. Epidemiology of hay fever and perennial allergic rhinitis. Allergy 1987; 21: 1–20

    CAS  Google Scholar 

  29. Friedlaender MH. Conjunctivitis of allergic origin: clinical presentation and differential diagnosis. Surv Ophthalmol 1993 Jul–Aug; 38 Suppl.: 105–14

    Article  PubMed  Google Scholar 

  30. Dart JKG, Buckley RJ, Monnickena M, et al. Perennial allergic conjunctivitis: definition, clinical characteristics and prevalence. Trans Ophthalmol Soc UK 1986; 105: 513–20

    PubMed  Google Scholar 

  31. Tuft SJ, Kemeny DM, Dart JKG, et al. Clinical features of atopic keratoconjunctivitis. Ophthalmology 1991; 98: 150–8

    PubMed  CAS  Google Scholar 

  32. Frankland AW, Easty D. Vernal keratoconjunctivitis: an atopic disease. Trans Ophthalmol Soc UK 1971; 91: 479–82

    PubMed  CAS  Google Scholar 

  33. Donshik PC. Giant papillary conjunctivitis. Trans Am Ophthalmol Soc 1994; 92: 687–744

    PubMed  CAS  Google Scholar 

  34. Brown MD, Potter JW. Floppy eyelid syndrome: a case report and clinical review. J Am Optom Assoc 1992 May; 63(5): 309–14

    PubMed  CAS  Google Scholar 

  35. Friedlaender MH. Contact allergy and toxicity in the eye. Int Ophthalmol Clin 1988; 28: 317–20

    Article  PubMed  CAS  Google Scholar 

  36. Hatinen A, Terasvirta M, Frakj JE. Contact allergy to components in topical ophthalmic preparations. Acta Ophthalmol (Copenh) 1985; 63: 424–6

    Article  CAS  Google Scholar 

  37. Sendle DP. Chemical hypersensitivity reactions. Int Ophthalmol Clin 1982; 26: 26–34

    Google Scholar 

  38. Moller C, Biorkksten B, Nilsson G, et al. The precision of the conjunctival provocation test. Allergy 1984; 39: 37–42

    Article  PubMed  CAS  Google Scholar 

  39. Kari O, Salo OP, Halmepuro L, et al. Tear histamine during allergic conjunctivitis challenge. Graefes Arch Clin Exp Ophthalmol 1985; 223: 60–2

    Article  PubMed  CAS  Google Scholar 

  40. Leonardi A, Fregona IA, Gismondi M, et al. Correlation between conjunctival provocation test (CPT) and systemic allergometric tests in allergic conjunctivitis. Eye 1990; 4: 760–4

    Article  PubMed  Google Scholar 

  41. Abelson MB, Chambers WA, Smith LM. Conjunctival allergen challenge. Arch Ophthalmol 1990 Jan; 108: 84–8

    Article  PubMed  CAS  Google Scholar 

  42. Tsubota K, Takamura E, Hasegawa T, et al. Detection by brush cytology of mast cells and eosinophils in allergic and vernal conjunctivitis. Cornea 1991; 10: 525–31

    Article  PubMed  CAS  Google Scholar 

  43. Horak F, Berger U, Menapace R, et al. Quantification of conjunctival vascular reaction by digital imaging. J Allergy Clin Immunol 1996; 98(3): 495–500

    Article  PubMed  CAS  Google Scholar 

  44. Abelson MB, Mediwale N, Weston JH. Conjunctival eosinophils in allergic ocular diseases. Arch Ophthalmol 1983; 101: 555–6

    Article  PubMed  CAS  Google Scholar 

  45. Rivasi F, Cavallini GM, Longanesi L. Cytology of allergic conjunctivitis: presence of airborne, nonhuman elements. Acta Cytol 1992 Jul–Aug; 36(4): 492–8

    PubMed  CAS  Google Scholar 

  46. Little EC, Garner LF. Eye protection from airborne allergens. J Am Optom Assoc 1986; 57: 462–4

    PubMed  CAS  Google Scholar 

  47. Dale S, Landmar E. Characterisation of allergens in a crude extract of Dermatophagoides farinae and their identification in a new purified preparation. Allergy 1985; 39: 572–85

    Article  Google Scholar 

  48. Durham SR, Varney V, Gaga M, et al. Immunotherapy and allergic inflammation. Clin Exp Allergy 1991 Jan; 21 Suppl. 1: 206–10

    Article  PubMed  Google Scholar 

  49. Ortolani C, Pastorello EA, Incorvaia C, et al. A double-blind, placebo-controlled study of immunotherapy with an alginate-conjugated extract of Parietaria judaica in patients with Parietaria hay fever. Allergy 1994 Jan; 49(1): 13–21

    Article  PubMed  CAS  Google Scholar 

  50. Varney VA, Gaga M, Frew AJ, et al. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 1991; 302: 265–9

    Article  PubMed  CAS  Google Scholar 

  51. Lofkvist T, Agrell B, Dreborg S, et al. Effects of immunotherapy with a purified standardized allergen preparation of Dermatophagoides farinae in adults with perennial allergic rhinoconjunctivitis. Allergy 1994 Feb; 49(2): 100–7

    Article  PubMed  CAS  Google Scholar 

  52. Del Prete A, Loffredo C, Carderopoli A, et al. Local specific immunotherapy in allergic conjunctivitis. Acta Ophthalmol (Copenh) 1994 Oct; 72(5): 631–4

    Article  Google Scholar 

  53. Altounyan REC. Review of the clinical activity and modes of action of sodium cromoglycate. In: Pepys J, Edwards AM, editors. The mast cell: its role in health and disease. London: Pitman Medical, 1979: 199–216

    Google Scholar 

  54. Bernstein IL, Johnson CL, Tse CST. Therapy with cromolyn sodium. Ann Intern Med 1978; 89: 228–33

    PubMed  CAS  Google Scholar 

  55. Foster CS. Evaluation of topical cromolyn sodium in the treatment of vernal keratoconjunctivitis. Ophthalmology 1988 Feb; 95(2): 194–201

    PubMed  CAS  Google Scholar 

  56. Dawson JP. Comparative trial of 2% sodium cromoglycate unit dose eye drops in seasonal allergic conjunctivitis. In: Pepys J, Edwards AM, editors. The mast cell: its role in health and disease. London: Pitman Medical, 1979: 506–11

    Google Scholar 

  57. Lindsay-Miller ACM. Group comparative trial of 2% sodium cromoglycate (Opticrom) with placebo in the treatment of seasonal allergic conjunctivitis. Clin Allergy 1979; 9: 279–5

    Google Scholar 

  58. Bec P, Berard P, Bonnet M, et al. Sodium cromoglycate eyewash in allergic conjunctivitis: multicentric controlled double-blind study. Review of the literature [in French]. J Fr Ophtalmol 1982; 5(11): 727–32

    PubMed  CAS  Google Scholar 

  59. Friday GA, Biglan AW, Hiles-DA, et al. Treatment of ragweed allergic conjunctivitis with cromolyn sodium 4% ophthalmic solution. Am J Ophthalmol 1983 Feb; 95(2): 169–74

    Article  PubMed  CAS  Google Scholar 

  60. Van Bijsterveld OP. A double-blind crossover study comparing sodium cromoglycate eye drops with placebo in the treatment of chronic conjunctivitis. Acta Ophthalmol (Copenh) 1984 Jun; 62(3): 479–84

    Article  Google Scholar 

  61. Hechanova Jr MG. A double blind study comparing sodium cromoglycate eye ointment with placebo in the treatment of chronic allergic conjunctivitis. Clin Trials J 1984; 21: 59–66

    Google Scholar 

  62. Kray KT, Squire EN, Tipton WR, et al. Cromolyn sodium in seasonal allergic conjunctivitis. J Allergy Clin Immunol 1985; 76: 623–7

    Article  PubMed  CAS  Google Scholar 

  63. Ruggieri ML, Scorcia G. Double blind group comparative trial of sodium cromoglycate eye treatment and placebo in the treatment of allergic eye diseases. Ann Allergy 1987; 58: 105–12

    Google Scholar 

  64. Meisler DM, Berzins UJ, Krachmer JH, et al. Cromolyn treatment of giant papillary conjunctivitis. Arch Ophthalmol 1982 Oct; 100(10): 1608–10

    Article  PubMed  CAS  Google Scholar 

  65. Kazadan JJ, Crawford JS, Langer H, et al. Sodium cromoglycate (Intal) in the treatment of vernal keratoconjunctivitis and allergic conjunctivitis. Can J Ophthalmol 1976 Oct; 11(4): 300–3

    Google Scholar 

  66. Tabbara KF, Arafat NT. Cromolyn effects on vernal keratoconjunctivitis in children. Arch Ophthalmol 1977 Dec; 95(12): 2184–6

    Article  PubMed  CAS  Google Scholar 

  67. Sayegh F, Samerra’e S, Khateeb M. Clinical trial of topical disodium cromoglycate in vernal keratoconjunctivitis. Ophthalmologica 1978; 177(4): 208–13

    Article  PubMed  CAS  Google Scholar 

  68. Foster SC, Duncan J. Randomized clinical trial of topically administrated cromolyn sodium for vernal keratoconjunctivitis. Am J Ophthalmol 1980; 92: 175–81

    Google Scholar 

  69. Juniper EF, Guyatt GH, Ferrie PJ, et al. Sodium cromoglycate eye drops: regular versus ‘as needed’ use in the treatment of seasonal allergic conjunctivitis. J Allergy Clin Immunol 1994 Jul; 94(1): 36–43

    Article  PubMed  CAS  Google Scholar 

  70. Leino M, Montan P, Nja F. A double-blind group comparative study of ophthalmic sodium cromoglycate, 2% four times daily and 4% twice daily, in the treatment of seasonal allergic conjunctivitis. Allergy 1994 Mar; 49(3): 147–51

    Article  PubMed  CAS  Google Scholar 

  71. Felius K, Van Bijsterveld OP. Effect of sodium cromoglycate on tear film break-up time. Ann Ophthalmol 1984; 16: 80–2

    PubMed  CAS  Google Scholar 

  72. Dixon M, Jackson DM, Richards IM. The action of sodium cromoglycate on C-fibre endings in the dog lung. Br J Pharmacol 1980; 70: 11–3

    Article  PubMed  CAS  Google Scholar 

  73. Kay AB, Walsh GM, Moqbel R, et al. Disodium cromoglycate inhibits activation of human inflammatory cells in vitro. J Allergy Clin Immunol 1987; 80: 1–8

    Article  PubMed  CAS  Google Scholar 

  74. Yuasa T, Tada R, Nakagwa Y, et al. Long term study of disodium cromoglycate eye drops in the treatment of vernal conjunctivitis [in Japanese]. Folia Ophthalmol Jpn 1982; 32: 2265–72

    Google Scholar 

  75. Moqbel R, Cromwell O, Kay AB. The effect of nedocromil sodium on human eosinophil activation. Drugs 1989; 37 Suppl. 1: 19

    Article  PubMed  CAS  Google Scholar 

  76. Borish L, Williams J, Johnson S, et al. Anti-inflammatory effects of nedocromil sodium: inhibition of alveolar macrophage function. Clin Exp Allergy 1992; 22: 984–90

    Article  PubMed  CAS  Google Scholar 

  77. Verleden GM, Belvisi MG, Stretton CD, et al. Nedocromil sodium modulates non-adrenergic, non-cholinergic broncho-constrictor nerves in guinea pig airways in vitro. Am Rev Respir Dis 1991; 143: 114–8

    PubMed  CAS  Google Scholar 

  78. Stockwell A, Easty DL. Group comparative trial of 2% nedocromil sodium with placebo in the treatment of seasonal allergic conjunctivitis. Eur J Ophthalmol 1994; 4: 19–23

    PubMed  CAS  Google Scholar 

  79. Leino M, Carlson C, Jaanio E, et al. Double-blind group comparative study of 2% nedocromil sodium eye drops with placebo eye drops in the treatment of seasonal allergic conjunctivitis. Ann Allergy 1990 Apr; 64(4): 398–402

    PubMed  CAS  Google Scholar 

  80. Blumenthal M, Casale T, Dockhorn R, et al. Efficacy and safety of Nedocromil Sodium ophthalmic solution in the treatment of seasonal allergic conjunctivitis. Am J Ophthalmol 1992; 113: 56–63

    PubMed  CAS  Google Scholar 

  81. Melamed J, Schwartz RH, Hirsch R, et al. Evaluation of nedocromil sodium 2% ophthalmic solution for the treatment of seasonal allergic conjunctivitis. Ann Allergy 1994; 73: 57–66

    PubMed  CAS  Google Scholar 

  82. Miglior M, Scullica L, Secchi AG, et al. Nedocromil sodium and astemizole, alone or combined, in the treatment of seasonal allergic conjunctivitis: a multicentre double blind clinical trial. Acta Ophthalmol (Copenh) 1993 Feb; 71(1): 73–8

    Article  CAS  Google Scholar 

  83. Leino M, Ennevaara K, Latvala AL, et al. Double-blind group comparative study of 2% nedocromil sodium eye drops with 2% sodium cromoglycate and placebo eye drops in the treatment of seasonal allergic conjunctivitis. Clin Exp Allergy 1992 Oct; 22(10): 929–32

    Article  PubMed  CAS  Google Scholar 

  84. Kjellman M. Clinical experience with Tilavist: an overview of efficacy and safety. Allergy 1995; 50 Suppl. 21: 14–22

    Article  PubMed  CAS  Google Scholar 

  85. Cerqueti PM, Ricaa V, Tosca MA, et al. Lodoxamide treatment of allergic conjunctivitis. Int Arch Allergy Immunol 1994; 105: 185–9

    Article  PubMed  CAS  Google Scholar 

  86. Santos CI, Huang AJ, Abelson MB, et al. Efficacy of lodoxamide 0.1% ophthalmic solution in resolving corneal epitheliopathy associated with vernal keratoconjunctivitis. Am J Ophthalmol 1994 Apr 15; 117(4): 488–97

    PubMed  CAS  Google Scholar 

  87. Caldwell DR, Verin P, Hartwich-Young R, et al. Efficacy and safety of lodoxamide 0.1% vs cromolyn sodium 4% in patients with vernal keratoconjunctivitis. Am J Ophthalmol 1992 Jun 15; 113(6): 632–7

    PubMed  CAS  Google Scholar 

  88. Yanni JM, Weimer M, Glaser RL, et al. Effect of lodoxamide on in vitro and in vivo conjunctival immediate hypersensitivity responses in rats. Int Arch Allergy Immunol 1993; 101: 102–6

    Article  PubMed  CAS  Google Scholar 

  89. Johnson HG. New antiallergy drugs — lodoxamide. Trends Pharmacol Sci 1980; 1: 343

    Article  CAS  Google Scholar 

  90. Frigas E, Reed CE. Effect of lodoxamide on allergy skin tests. J Allergy Clin Immunol 1980; 65: 257–62

    Article  PubMed  CAS  Google Scholar 

  91. Floyd R, Kalpaxis J, Thayer T, et al. Double blind comparison of HEPP (IgE pentapeptide) 0.5% ophthalmic solution and sodium cromoglycate ophthalmic solution, USP 4% in patients having allergic conjunctivitis. Invest Ophthalmol Vis Sci 1988; 29: 45

    Google Scholar 

  92. Kalpaxis JG, Austin TX. Clinical comparison of IgE pentapeptide (HEPP) and cromolyn (Opticrom) in allergic conjunctivitis. Ann Allergy 1987; 85: 291

    Google Scholar 

  93. Corre A, Greze JF, Mounier G, et al. Intraindividual double-blind comparative study of the immediate ocular tolerability of the Na+ and Mg++ salts of N-acetyl-aspartylglutamic acid (NAAGA). J Fr Ophtalmol 1991; 14: 559–63

    PubMed  CAS  Google Scholar 

  94. Meijer F, Pogany K, Kok JH, et al. N-acetyl-aspartyl glutamic acid (NAAGA) topical eyedrops in the treatment of giant papillary conjunctivitis (GPC). Doc Ophthalmol 1993; 85(1): 5–11

    Article  PubMed  CAS  Google Scholar 

  95. Favennec F, Cartos A. Zinc and seasonal conjunctivitis [in French]. Allerg Immunol (Paris) 1993; 25: 119–22

    CAS  Google Scholar 

  96. Duzman E, Warman A, Warman R. Efficacy and safety of topical oxymetazoline in treating allergic and environmental conjunctivitis. Ann Ophthalmol 1986 Jan; 18(1): 28–31

    PubMed  CAS  Google Scholar 

  97. Breakey AS, Cinotti AA, Hirshman A, et al. A double blinded, multicentre controlled trial of 0.025% oxymetazoline ophthalmic solution in patients with allergic and non-infectious conjunctivitis. Pharmacotherapeutica 1980; 2: 353–6

    CAS  Google Scholar 

  98. Gilman AG, Goodman LS, Filman A, editors. Goodman and Gilmans the pharmacological basis of therapeutics. 6th ed. New York: Macmillan, 1980: 168–72

    Google Scholar 

  99. Abelson MB, Butrus SI, Weston JH, et al. Tolerance and absence of rebound vasodilatation following topical ocular decongestant usage. Ophthalmology 1984; 91: 1364–7

    PubMed  CAS  Google Scholar 

  100. Norman PS. Newer antihistaminic agents. J Allergy Clin Immunol 1985; 76: 366

    Article  PubMed  CAS  Google Scholar 

  101. Ciprandi G, Buscaglia S, Pesce G, et al. Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early- and late-phase reactions after allergen-specific challenge. J Allergy Clin Immunol 1995; 95: 612–21

    Article  PubMed  CAS  Google Scholar 

  102. Panayotopoulos SM, Panayotopoulos ES. Efficacy of cetirizine in the treatment of seasonal allergic rhinoconjunctivitis. Ann Allergy 1990; 65: 146–8

    PubMed  CAS  Google Scholar 

  103. Gambardella R. A comparison of the efficacy of azelastine nasal spray and loratidine tablets in the treatment of seasonal allergic rhinitis. J Int Med Res 1993 Sep–Oct; 21(5): 268–75

    PubMed  CAS  Google Scholar 

  104. Boland N. A double blind study of astemizole and terfenadine in the treatment of perennial allergic rhinitis. Ann Allergy 1988; 61: 18–24

    PubMed  CAS  Google Scholar 

  105. Miglior M, Scullica L, Secchi AG, et al. Nedocromil sodium and astemizole, alone or combined, in the treatment of seasonal allergic conjunctivitis: a multicentre double blind clinical trial. Acta Ophthalmol (Copenh) 1993; 71: 73–8

    Article  CAS  Google Scholar 

  106. Juniper EF, White J, Dolovich J. Efficacy of continuous treatment with astemizole (Hismanal) and terfenadine (Seldane) in ragweed pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol 1988; 82: 670–5

    Article  PubMed  CAS  Google Scholar 

  107. Leclercq-Foucart J, Fernere A, Vanden Bussche G. A double blind trial comparing astemizole and ketotifen in the suppression of hay fever symptoms. Curr Ther Res 1986; 39: 875–83

    Google Scholar 

  108. Saito Y, Baba S, Furuuchi I, et al. Double blind comparative study of terfenadine vs ketotifen on perennial allergic rhinitis. Otorhinolaryngology 1988; 31 Suppl. 7: 963–4

    Google Scholar 

  109. Grant SM, Goa KL, Fitton A, et al. Ketotifen: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders. Drugs 1990; 40: 412–48

    Article  PubMed  CAS  Google Scholar 

  110. Ciprandi G, Buscaglia S, Pesce GP, et al. Protective effect of loratadine on specific conjunctival provocation test. Int Arch Allergy Appl Immunol 1991; 96: 344–7

    Article  PubMed  CAS  Google Scholar 

  111. Ciprandi G, Buscaglia S, Catrullo A, et al. Loratadine in the treatment of cough associated with allergic rhinoconjunctivitis. Ann Allergy Asthma Immunol 1995; 75: 115–20

    PubMed  CAS  Google Scholar 

  112. Olsen OT, Nuchel Petersen L, Hoi L, et al. Comparison of loratadine and terfenadine in allergic seasonal rhinoconjunctivitis with emphasis on nasal stuffiness and peak flow. Arzneimittel Forschung 1992; 42: 1227–31

    PubMed  CAS  Google Scholar 

  113. Ciprandi G, Buscaglia S, Iudice A, et al. Protective effect of different doses of terfenadine on the conjunctival provocation test. Allergy 1992; 47: 309–12

    Article  PubMed  CAS  Google Scholar 

  114. Kjellman NI, Andersson B. Terfenadine reduces skin and conjunctival reactivity in grass pollen allergic children. Clin Allergy 1986; 16: 441–9

    Article  PubMed  CAS  Google Scholar 

  115. Pipkorn U, Bende M, Hedner J, et al. A double-blind evaluation of topical levocabastine, a new specific H1 antagonist in patients with allergic conjunctivitis. Allergy 1985 Oct; 40(7): 491–6

    Article  PubMed  CAS  Google Scholar 

  116. Bende M, Pipkorn U. Topical levocabastine, a selective H1 antagonist, in seasonal allergic rhinoconjunctivitis. Allergy 1987 Oct; 42(7): 512–5

    Article  PubMed  CAS  Google Scholar 

  117. Bischoff P, Gerber M. Multicenter evaluation of a new local antihistaminic drug (levocabastine) [in German]. Klin Monatsbl Augenheilkd 1992; 200(5): 354–7

    Article  PubMed  CAS  Google Scholar 

  118. Janssens MM, Vanden Bussche G. Levocabastine: an effective topical treatment of allergic rhinoconjunctivitis. Clin Exp Allergy 1991 May; 21 Suppl. 2: 29–36

    Article  PubMed  Google Scholar 

  119. Vermeulen J, Mercer M. Comparison of the efficacy and tolerability of topical levocabastine and sodium cromoglycate in the treatment of seasonal allergic rhinoconjunctivitis in children. Pediatr Allergy Immunol 1994; 5: 209–13

    Article  PubMed  CAS  Google Scholar 

  120. The Livostin Study Group. A comparison of topical levocabastine and oral terfenadine in the treatment of allergic rhinoconjunctivitis. Allergy 1993 Oct; 48(7): 530–4

    Article  Google Scholar 

  121. Sohoel P, Freng BA, Kramer J, et al. Topical levocabastine compared with orally administered terfenadine for the prophylaxis and treatment of seasonal rhinoconjunctivitis. J Allergy Clin Immunol 1993 Jul; 92 (1 Pt 1): 73–81

    Article  PubMed  CAS  Google Scholar 

  122. Odelram H, Bjorksten B, Klercker T, et al. Topical levocabastine versus sodium cromoglycate in allergic conjunctivitis. Allergy 1989 Aug; 44(6): 432–6

    Article  PubMed  CAS  Google Scholar 

  123. Ciprandi G, Cerqueti PM, Sacca S, et al. Levocabastine versus cromolyn sodium in the treatment of pollen-induced conjunctivitis. Ann Allergy 1990 Aug; 65(2): 156–8

    PubMed  CAS  Google Scholar 

  124. Frostad AB, Olsen AK. A comparison of topical levocabastine and sodium cromoglycate in the treatment of pollen-provoked allergic conjunctivitis. Clin Exp Allergy 1993; 23: 406–9

    Article  PubMed  CAS  Google Scholar 

  125. Swedish GP Allergy Team. Topical levocabastine compared with oral loratadine for the treatment of seasonal allergic rhinoconjunctivitis. Allergy 1994; 49: 611–5

    Article  Google Scholar 

  126. Graue E. Effects of levocabastine ophthalmic solution (H1 receptor antagonist) on symptoms of vernal conjunctivitis: a prospective, randomised double-blind study [in Spanish]. Gac Med Mex 1994; 130(6): 481–6

    PubMed  CAS  Google Scholar 

  127. Goes F, Blockhuys S, Janssens M. Levocabastine eye drops in the treatment of vernal conjunctivitis. Doc Ophthalmol 1994; 87(3): 271–81

    Article  PubMed  CAS  Google Scholar 

  128. Zuber P, Pecoud A. Effect of levocabastine, a new H1 antagonist, in a conjunctival provocation test with allergens. J Allergy Clin Immunol 1988; 82(4): 590–4

    Article  PubMed  CAS  Google Scholar 

  129. Rimas M, Kjellman NI, Blychert LO, et al. Topical levocabastine protects better than sodium cromoglycate and placebo in conjunctival provocation tests. Allergy 1990; 45: 18–21

    Article  PubMed  CAS  Google Scholar 

  130. Abelson MB, George MA, Schaefer K, et al. Evaluation of the new ophthalmic antihistamine, 0.05% levocabastine, in the clinical allergen challenge model of allergic conjunctivitis. J Allergy Clin Immunol 1994 Sep; 94 (3 Pt 1): 458–64

    Article  PubMed  CAS  Google Scholar 

  131. Abelson MB, George MA, Smith LM. Evaluation of 0.05% levocabastine versus 4% sodium cromolyn in the allergen challenge model. Ophthalmology 1995; 102: 310–6

    PubMed  CAS  Google Scholar 

  132. Janssens M. Efficacy of levocabastine in conjunctival provocation studies. Doc Ophthalmol 1992; 82: 341–51

    Article  PubMed  CAS  Google Scholar 

  133. Abelson MB, Smith LM. Evaluation in the histamine and compound 48/80 models of ocular allergy in humans. Ophthalmology 1988; 95: 1494–7

    PubMed  CAS  Google Scholar 

  134. Van Wauwe JP. Animal pharmacology of levocabastine: a new type of H1-antihistamine well suited for topical application. In: Mygind N, Naclerio RM, editors. Rhinoconjunctivitis: new perspectives in topical treatment. Proceedings of the XIIIth International Congress of Allergology and Clinical Immunology; 1988 Oct; Montreux: 27–34

  135. Abelson MB, Weintraub D. Levocabastine eye drops: a new approach for the treatment of acute allergic conjunctivitis. Eur J Ophthalmol 1994; 4(2): 91–101

    PubMed  CAS  Google Scholar 

  136. McTavish D, Sorkin EM. Azelastine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 1989: 38(5): 778–798

    Article  PubMed  CAS  Google Scholar 

  137. Ciprandi G, Buscaglia S, Catrullo A, et al. Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert anti-allergic activity. Clin Exp Allergy 1996; 27: 182–91

    Article  Google Scholar 

  138. Giede-Tuch C, Bousquet J, Chuchalin AD, et al. Multinational investigation of the efficacy and safety of azelastine eye drops in the treatment of allergic conjunctivitis. Allergy 1997; 52 Suppl. 37: 199

    Google Scholar 

  139. Giede-Tuch C, Metzenauer P, Petzold U. Investigation of the efficacy and safety of azelastine, levocabastine and placebo eye drops in patients with seasonal allergic conjunctivitis. Allergy 1997; 52 Suppl. 37: 199

    Google Scholar 

  140. Siegel SC. Overview of corticosteroids therapy. J Allergy Clin Immunol 1985; 76: 312–20

    Article  PubMed  CAS  Google Scholar 

  141. Shin DH, Frenkel RE, David R, et al. Effect of topical anti-inflammatory treatment on the outcome of laser trabeculoplasty: the Fluorometholone-Laser Trabeculoplasty Study Group. Am J Ophthalmol 1996; 122(3): 349–54

    PubMed  CAS  Google Scholar 

  142. Holsclaw DS, Whitcher JP, Wong IG, et al. Supratarsal injection of corticosteroids in the treatment of refractory vernal keratoconjunctivitis. Am J Ophthalmol 1996; 121: 243–9

    PubMed  CAS  Google Scholar 

  143. Abelson MB, Sloan J. Nonsteroidal anti-inflammatory drugs: current ophthalmic therapy. J Fla Med Assoc 1994; 81: 261–3

    PubMed  CAS  Google Scholar 

  144. Vane J. The evaluation of non steroidal anti-inflammatory drugs and their mechanisms of action. Drugs 1987; 33 Suppl. 1: 18

    Article  PubMed  CAS  Google Scholar 

  145. Abramson SB, Weissman G. The mechanisms of action of non-steroidal anti-inflammatory drugs. Arthritis Rheum 1989; 32: 1

    Article  PubMed  CAS  Google Scholar 

  146. Abelson MB, Butrus SI, Weston SM. Aspirin therapy in vernal conjunctivitis. Am J Ophthalmol 1983; 95: 502–5

    PubMed  CAS  Google Scholar 

  147. Lemrini F, Dafrallah L, Sebbahi F, et al. Treatment of vernal conjunctivitis with aspirin. Rev Int Trach Pathol Ocul Trop Subtrop Sante Publique 1989; 66: 119–27

    PubMed  CAS  Google Scholar 

  148. Sacca S, Cerqueti PM, Rolando M, et al. Limpiego per via topica di aspirina nelle congiuntiviti allergiche. Boll Ocul 1988; 67: 193–7

    Google Scholar 

  149. Tauber J, Abelson M, Ostrov C, et al. A multicenter comparison of diclofenac sodium 0.1% and ketotorolac tromethamine 0.5% in patients with acute seasonal allergic conjunctivitis. Invest Ophthalmol Vis Sci 1994; 35 Suppl.: 1921

    Google Scholar 

  150. Van Husen H. Topical treatment of anterior ocular disease with diclofenac Na eye drops. Klin Monatsbl Augenheilkd 1986; 188: 615–9

    Article  PubMed  Google Scholar 

  151. Murphy JE. Drug profile: Tanderil eye ointment. J Int Med Res 1973; 1: 136–40

    CAS  Google Scholar 

  152. Kaufmann Y, Chang AE, Robb RJ, et al. Mechanisms of action of cyclosporine A: inhibition of lymphokine secretion studied with antigen stimulated T cell hybridomas. J Immunol 1984; 133: 3107–11

    PubMed  CAS  Google Scholar 

  153. Okudaira H, Sakurai L, Terado K, et al. Cyclosporine A-induced supression of ongoing IgE antibody formation in the mouse. Int Arch Allergy Appl Immunol 1986; 79: 164–8

    Article  PubMed  CAS  Google Scholar 

  154. Kaan G, Ozden O. Therapeutic use of topical cyclosporine. Ann Ophthalmol 1993; 25: 182–6

    PubMed  CAS  Google Scholar 

  155. Bleik JH, Tabbara KF. Topical cyclosporine in vernal keratoconjunctivitis. Ophthalmology 1991; 98: 1679–84

    PubMed  CAS  Google Scholar 

  156. Secchi AG, Tognon MS, Leonardi A. Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis. Am J Ophthalmol 1990; 110: 641–5

    PubMed  CAS  Google Scholar 

  157. Wiens JJ, Jackson WB. New directions in therapy for ocular allergy. Int Ophthalmol Clin 1988; 28: 332–7

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute for Medical Statistics, Informatics and Epidemiology, Medical Faculty, University of Cologne, D-50924, Cologne, Germany

    Ralph Mösges

  2. Department of Otorhinolaryngology, Plastic Head and Neck Surgery, Medical Faculty, University of Aachen, Germany

    Hassan A. Hassan

  3. Department of Ophthalmology, Medical Faculty, University of Aachen, Germany

    Martin R. Wenzel

Authors
  1. Ralph Mösges
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hassan A. Hassan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Martin R. Wenzel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ralph Mösges.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mösges, R., Hassan, H.A. & Wenzel, M.R. Optimal Use of Topical Agents for Allergic Conjunctivitis. BioDrugs 8, 250–264 (1997). https://doi.org/10.2165/00063030-199708040-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-199708040-00002

Keywords

Search

Navigation